LIRAGLUTIDE

India plans to incentivize local manufacturing of GLP-1 drugs, crucial for treating diabetes and obesity, starting in 2026, as per a government official speaking to Reuters. These drugs, originally approved for diabetes treatment, are also used for ...

People are going to great lengths to obtain popular weight-loss drugs. They are stashing injectables in their carry-on luggage, buying counterfeit formulas online, and importing boxes from Europe. The treatments have sparked extensive media coverage...

Biocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio to address weight management needs and tapping into a USD 47 million market opportunity. Biocon said the total ...

Kiran Mazumdar-Shaw of Biocon aims to consolidate, accelerate biosimilar business, and reduce debt after Viatris acquisition in FY25. Mazumdar-Shaw anticipates expanding its market share for biosimilar products across the US, Europe, and emerging ma...

Biocon partners with Medix to distribute Liraglutide for chronic weight management in Mexico, offering affordable obesity treatment options. The collaboration aims to improve patient access and quality of life in a country with high obesity rates.

Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife fo...

Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based company secured UK approval for the first generic version of liraglutide inje...

Eli Lilly has commenced phase three clinical trials in India for a new oral weight-loss drug called orforglipron. The trials aim to assess its safety and efficacy compared to insulin glargine in individuals with Type 2 diabetes and obesity or overwe...

The year 2024, started with a correction in nifty, but one set of stocks which were able to outperform were pharma stocks. While it might appear to be a sudden up move, if one looks at what has happened in the pharma sector in the last eight years, ...

​​ The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement.

New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diabetes patients.

In the last few weeks, the range in which the nifty had been moving has become broader as the volatility has increased both due to international and domestic reasons. It is very likely that that market may stay in this range and mode, till the time ...

As the market moves from clearly bullish mode to volatile mode with a bearish bias, there will be readjustment in valuation across markets. Over the next few weeks both domestic and international news flow have a high probability of making broader m...

Fake weight loss injections, falsely marketed as Ozempic or Saxenda, have triggered significant safety alarms in the United Kingdom. Authorities are cautioning the public about the substantial risks associated with these counterfeit products, as sev...

While the correction has been going on in the market since the middle of July, it is only on days like Monday where everyone on the street feels that equity markets are correcting. It is only a matter of time that the concept of relative valuation w...

Counterfeit injection pens falsely labeled as Ozempic, a popular diabetes drug also used for weight loss, have been discovered in Europe, according to drug authorities. The fake pens originated from wholesalers in Austria and Germany, and found at s...

Titan Co has clocked 20% year-on-year growth in its revenues for the second quarter ended September 2023. A total of 81 stores were added in this period, taking the group’s retail presence to 2,859 stores.

Except for a pocket in which demand for covid drugs led to sharp surge in pharma stocks, the pharma sector had been under pressure for a long time. After a long phase of consolidation, in which some companies have implemented change in their busines...

​​​India contributed about a fifth or ₹4,196 crore of the company's overall sales of ₹21,439 crore in 2021-22, but domestic business has clocked 17% compound annual growth rate in the past four financial years, well above the sector average of 9-10%.